Raymond James Financial Inc. Takes $16.91 Million Position in Glaukos Co. (NYSE:GKOS)

Raymond James Financial Inc. bought a new stake in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 112,771 shares of the medical instruments supplier's stock, valued at approximately $16,910,000. Raymond James Financial Inc. owned 0.20% of Glaukos as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GKOS. Renaissance Technologies LLC raised its stake in shares of Glaukos by 30.6% during the fourth quarter. Renaissance Technologies LLC now owns 49,600 shares of the medical instruments supplier's stock valued at $7,437,000 after purchasing an additional 11,608 shares during the period. FIL Ltd purchased a new stake in Glaukos during the 4th quarter worth $1,063,000. Invesco Ltd. grew its stake in shares of Glaukos by 4.9% during the fourth quarter. Invesco Ltd. now owns 1,458,635 shares of the medical instruments supplier's stock valued at $218,708,000 after acquiring an additional 68,310 shares in the last quarter. Federated Hermes Inc. increased its position in shares of Glaukos by 1.8% during the fourth quarter. Federated Hermes Inc. now owns 28,224 shares of the medical instruments supplier's stock worth $4,232,000 after acquiring an additional 501 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its stake in shares of Glaukos by 3.3% in the fourth quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier's stock worth $345,000 after acquiring an additional 73 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have issued reports on GKOS. Mizuho dropped their price objective on Glaukos from $200.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday, April 16th. Stifel Nicolaus lifted their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, December 31st. Needham & Company LLC increased their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Wells Fargo & Company boosted their target price on shares of Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Finally, Truist Financial reduced their price target on shares of Glaukos from $185.00 to $140.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $156.17.

Glaukos Stock Performance

NYSE GKOS traded down $1.59 during trading hours on Friday, hitting $93.84. The company had a trading volume of 130,830 shares, compared to its average volume of 641,587. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The firm has a market cap of $5.31 billion, a P/E ratio of -32.70 and a beta of 0.88. Glaukos Co. has a fifty-two week low of $77.91 and a fifty-two week high of $163.71. The business has a fifty day simple moving average of $103.49 and a 200-day simple moving average of $130.35.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Equities analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Insider Activity

In other news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company's stock, valued at approximately $5,708,568.04. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.